sponsored
PatientsVille.com Logo

PatientsVille

Brilique Medical Research Studies

Up-to-date List of Brilique Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Brilique Medical Research Studies

Rank Status Study
1 Recruiting High Ticagrelor Loading Dose in STEMI
Condition: Coronary Artery Disease
Interventions: Drug: Ticagrelor 180mg;   Drug: Ticagrelor 270mg;   Drug: Ticagrelor 360mg
Outcome Measures: Platelet reactivity;   Platelet function profiles by VerifyNow;   Platelet function profiles by VASP
2 Recruiting Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor.
Condition: Platelet Reactivity
Interventions: Drug: Clopidogrel and Ticagrelor;   Drug: Ticagrelor
Outcome Measures: Platelet Reactivity between the two groups at 24 hours;   Platelet reactivity between the two groups at 4 hours
3 Not yet recruiting In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients
Condition: Coronary Artery Disease
Interventions: Drug: Ticagrelor 180mg;   Drug: Ticagrelor 90mg
Outcome Measure: Platelet function
4 Recruiting Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
Conditions: Coronary Artery Disease;   Acute Coronary Syndrome
Interventions: Drug: Ticagrelor 180mg;   Drug: Prasugrel 10mg;   Drug: Ticagrelor 90mg
Outcome Measure: Platelet reactivity
5 Recruiting Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion
Condition: Acute Coronary Syndrome
Interventions: Drug: ticagrelor;   Drug: Eptifibatide
Outcome Measures: Change in percent inhibition of platelet activity;   Correlations between platelet activity inhibition
6 Recruiting Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects
Condition: Kidney Failure, Chronic
Intervention: Drug: ticagrelor
Outcome Measures: Change in maximum plasma concentration of ticagrelor and its active metabolite AR-C124910XX.;   Change in inhibition of platelet aggregation and platelet reactivity
7 Not yet recruiting Comparison of The Influence of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function
Condition: ST-Segment Elevation Myocardial Infarction
Interventions: Drug: Ticagrelor;   Drug: Clopidogrel
Outcome Measure: CD40 Ligand(CD40l)/C-reactive protein(CRP)/P-selectin and Circulating Endothelial Cells(CECs)
8 Recruiting Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients
Condition: Coronary Artery Disease
Interventions: Drug: Ticagrelor;   Drug: Clopidogrel
Outcome Measures: Compare ticagrelor's versus clopidogrel's inhibition of the P2Y12 receptor as measured by the decrease in P2Y12 Reaction Units (PRU) using VerifyNow TM.;   Compare the decrease of P2Y12 Reaction Units (PRU) by VerifyNow TM from ticagrelor and clopidogrel.;   Compare the decrease in P2Y l2 Reaction Units (PRU) by VerifyNow™ from ticagrelor's and clopidogrel's morning dose on Day 7;   To evaluate and compare the pharmacodynamic effects, measured by the vasodilator-stimulated phosphoprotein (VASP) assay (platelet reactivity index [PRI]), in all subjects;   Assess and to compare the percentage of subjects with High on-treatment Platelet Reactivity (HPR) at all time points after randomized study treatment.
9 Recruiting Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG
Conditions: Coronary Artery Desease,;   Stable Angina,;   Acute Coronary Syndrome
Interventions: Drug: Ticagrelor;   Drug: Aspirin;   Drug: Placebo - Ticagrelor;   Drug: Placebo - Aspirin
Outcome Measures: MACCE;   Cardiovascular death;   Major bleeding events;   All cause death;   Myocardial Infarction;   Target Lesion Revascularization;   Stroke
10 Recruiting A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Ticagrelor 90 mg;   Drug: Ticagrelor placebo
Outcome Measures: Time from randomisation to first occurrence of any event from the composite of CV death, MI or stroke;   Time from randomisation to first occurrence of any event from the composite of all-cause death, MI or stroke;   Time from randomisation to death of CV cause;   Time from randomisation to death of any cause
11 Not yet recruiting Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis
Conditions: Acute ST Segment Elevation Myocardial Infarction;   Acute Coronary Syndrome
Interventions: Drug: Ticagrelor;   Drug: Clopidogrel
Outcome Measures: Pharmacodynamics (PRU and IPA) of ticagrelor vs Clopidogrel using VASP and VerifyNow;   Pharmacokinetic (AUC, Cmax, Tmax)
12 Recruiting Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS
Condition: Non ST Segment Elevation Acute Coronary Syndrome
Interventions: Drug: Ticagrelor;   Drug: Clopidogrel
Outcome Measure: Micro-RNA and microparticles
13 Recruiting Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )
Conditions: Acute Coronary Syndrome;   Adverse Reaction to Antiplatelet Agent
Interventions: Drug: Ticagrelor mashed pills;   Drug: Ticagrelor integral pills
Outcome Measures: residual platelet reactivity;   high residual platelet reactivity;   Bleeding events;   Dyspnoea and/or symptomatic bradycardia
14 Recruiting Ticagrelor China Pharmacokinetic/Pharmacodynamic Study
Condition: Stable Coronary Heart Disease (CHD)
Intervention: Drug: Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor)
Outcome Measures: Pharmacodynamic;   Pharmacokinetics;   Safety
15 Recruiting Ticagrelor vs Clopidogrel Effect on MFR in CAD Population
Condition: Coronary Artery Disease
Interventions: Drug: Ticagrelor;   Drug: Clopidogrel
Outcome Measures: Differences in rest MBF, stress MBF and MBFR between ticagrelor and clopidogrel treated patients as measured by PET;   The effect of ticagrelor on rest MBF, stress MBF and MBFR will be compared in the normal versus abnormal segments on a segmental and patient basis in the ticagrelor treated subjects
16 Recruiting Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients
Conditions: Type-2 Diabetes Mellitus;   Coronary Artery Disease
Interventions: Drug: Ticagrelor + Aspirin;   Drug: Clopidogrel + Aspirin
Outcome Measures: Thrombus formation;   Platelet reactivity;   Vasodilator-Stimulated Phosphoprotein phosphorylation assay
17 Recruiting Impact of Ticagrelor Re-load on Pharmacodynamic Profiles
Condition: Coronary Artery Disease
Intervention: Drug: Ticagrelor re-load
Outcome Measures: platelet reactivity index (PRI);   Platelet reactivity
18 Not yet recruiting Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel
Conditions: Diabetes Mellitus;   Coronary Disease
Interventions: Drug: Ticagrelor;   Drug: Continued clopidogrel
Outcome Measures: Rate of elevation of troponin or CK-MB (above the upper limit of normal, and above 3 times the upper limit of normal) measured 20-24 hours after the PCI.;   Rate of major adverse cardiovascular endpoints including death, myocardial infarction or urgent target vessel revascularization at 30 days
19 Recruiting Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing
Condition: Coronary Heart Disease
Interventions: Drug: Ticagrelor;   Drug: Prasugrel
Outcome Measures: ADP-induced platelet aggregation after randomized treatment with ticagrelor or prasugrel;   Proportion of low responders in ticagrelor or prasugrel group;   Proportion of enhanced responders in ticagrelor or prasugrel group
20 Recruiting Clopidogrel And Ticagrelor in Healthy Subjects
Condition: Pharmacodynamics of Antiplatelet Agent.
Interventions: Drug: Ticagrelor 90 mg;   Drug: Clopidogrel 600 mg
Outcome Measure: Platelet reactivity

These studies may lead to new treatments and are adding insight into Brilique etiology and treatment.

A major focus of Brilique research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Brilique